Cellbricks‘ proprietary light-based biofabrication system introduces a novel and automated approach to producing human tissue therapeutics – enabling scalability and speed beyond other methods – supported by AI-powered tissue engineering.
Cellbricks Therapeutics advances two programs—soft tissue therapeutics for wounds and liver tissue—to restore organ function in patients with severe conditions.
The company combines scientific, clinical, and business expertise to develop tissue-based therapies, supported by over 100 years of tissue engineering experience.
Cellbricks Therapeutics develops implantable tissue grafts using biofabrication, biomaterials, and human cells to restore tissue function in regenerative medicine.
A tissue therapeutics company – built on DeepTech innovation – offering a scalable solution to restore lost tissue and organ function for millions of patients.